Data fra et tredje langtidsforsøg, ADAPT (The Alzheimer’ s Disease Anti- inflammatory Prevention Trial), viser ikke signifikant øget kardiovaskulær risiko med celecoxib 200 mg 2 gange dagligt sammenlignet med placebo.
Data from a third long-term study, ADAPT (The Alzheimer's Disease Anti-inflammatory Prevention Trial), did not show a significantly increased cardiovascular risk with celecoxib 200mg BID compared to placebo.